Bill Few Associates Inc. Has $869,000 Stake in Stryker Co. (NYSE:SYK)

Bill Few Associates Inc. lowered its stake in Stryker Co. (NYSE:SYK) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,406 shares of the medical technology company’s stock after selling 50 shares during the period. Bill Few Associates Inc.’s holdings in Stryker were worth $869,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Centaurus Financial Inc. lifted its stake in shares of Stryker by 10.9% during the fourth quarter. Centaurus Financial Inc. now owns 878 shares of the medical technology company’s stock valued at $263,000 after acquiring an additional 86 shares during the period. SageView Advisory Group LLC boosted its stake in shares of Stryker by 17.1% in the 4th quarter. SageView Advisory Group LLC now owns 1,627 shares of the medical technology company’s stock valued at $515,000 after purchasing an additional 237 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in shares of Stryker during the 4th quarter worth approximately $1,203,000. Nomura Holdings Inc. raised its stake in shares of Stryker by 241.7% during the fourth quarter. Nomura Holdings Inc. now owns 6,834 shares of the medical technology company’s stock worth $2,047,000 after buying an additional 4,834 shares during the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new position in Stryker in the fourth quarter valued at approximately $178,000. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on SYK. Wolfe Research assumed coverage on shares of Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 target price for the company. Stifel Nicolaus dropped their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. BTIG Research raised their target price on Stryker from $374.00 to $383.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial upped their price target on Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a research note on Monday. Finally, StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $381.16.

Stryker Stock Performance

SYK opened at $358.98 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. The company has a market capitalization of $136.80 billion, a price-to-earnings ratio of 40.02, a P/E/G ratio of 2.78 and a beta of 0.91. The business’s 50-day moving average price is $353.45 and its two-hundred day moving average price is $342.96. Stryker Co. has a 1 year low of $255.22 and a 1 year high of $374.63.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.79 by $0.02. The firm had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.54 EPS. Equities analysts expect that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.89%. Stryker’s payout ratio is currently 35.67%.

Insiders Place Their Bets

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at approximately $949,716. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 190,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the transaction, the director now directly owns 3,316,608 shares in the company, valued at $1,072,790,023.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock valued at $71,811,372 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.